Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study

Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study

Abstract Background Cigarette smoking is the leading preventable cause of premature death. Despite dedicated programmes, quit rates remain low due to barriers such as nicotine withdrawal syndrome or post-cessation weight gain. Glucagon-like peptide-1 (GLP-1) analogues reduce energy intake and body w...

Full description

Bibliographic Details
Main Authors: Sophia Lengsfeld, Thilo Burkard, Andrea Meienberg, Nica Jeanloz, David Coynel, Deborah R. Vogt, Lars G. Hemkens, Benjamin Speich, Davide Zanchi, Tobias E. Erlanger, Mirjam Christ-Crain, Bettina Winzeler
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Trials
Subjects:
Cigarette smoking
GLP-1 analogues
Dulaglutide
Weight gain
Prevalence abstinence rate
Diabetes
Online Access:https://doi.org/10.1186/s13063-023-07164-9

Internet

https://doi.org/10.1186/s13063-023-07164-9

Similar Items